Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Akobeng, Anthony K ^a   Stokkers, Pieter C ^b  

^a BOOTH HALL CHILDREN S HOSPITAL   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; PLACEBO; THALIDOMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

BIRTH DEFECT; CROHN DISEASE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; NEURALGIA; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT OUTCOME; DRUG ANTAGONISM; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EVENING DOSAGE; HEADACHE; MORBIDITY; MORTALITY; NAUSEA; RASH; TREATMENT RESPONSE; ULCERATIVE COLITIS;

CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349132059     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007351.pub2     Document Type: Review

References (21)

1. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16(6):1117-1124 (Pubitemid 34680754)
2. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, et al.Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17(2):135-139
3. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50(2):196-200. (Pubitemid 34087931)
4. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65.
5. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117(6):1271-1277
6. Gupta P, Andrew H, Kirschner BS. Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab. Gastroenterology 2003;124(4):A525.
7. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-1549 (Pubitemid 34621118)
8. Higgins JP, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] ; Section 6. In: The Cochrane Library, Issue 3 2005. Chichester, UK: John Wiley & Sons Ltd.
9. Jadad AR, Moore RA, Carroll D, Jenkison C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1-12. (Pubitemid 26120810)
10. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002;35(2):149-150 (Pubitemid 34815853)
11. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
12. Meierhofer C, Wiedermann CJ. New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel 2003;6(1):92-99 (Pubitemid 36206943)
13. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Protein kinase C-dependent effects on leukocyte migration of thalidomide. J Infect Dis 1999;180(1):216-219 (Pubitemid 29293940)
14. Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007;25(5):557-567 (Pubitemid 46255858)
15. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al.Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-769 (Pubitemid 29468216)
16. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16(6):1117-1124 (Pubitemid 34680754)
17. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, Macintosh DG, et al.Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-1239 (Pubitemid 47300424)
18. Sands BE, Podolsky DK. New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology 1999;117(6):1485-1488
19. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al.Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-885 (Pubitemid 38252535)
20. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al.Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-250 (Pubitemid 47080388)
21. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al.An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117(6):1278- 1287